The JAG2 Knockout LoVo Polyclonal Cells are a CRISPR/Cas9?edited polyclonal knockout cell population derived from the LoVo human colorectal adenocarcinoma epithelial cell line. These polyclonal knockout cells feature targeted disruption of the JAG2 gene, eliminating functional Jagged?2 ligand expression across the mixed population. This loss?of?function model provides a powerful tool for investigating Notch?dependent signaling in a physiologically relevant metastatic colorectal cancer context without the limitations of single?clone variability. The polyclonal format captures the heterogeneity of CRISPR?mediated gene disruption, offering robust and reproducible in vitro phenotypes suitable for high?content studies.
The host cell line, LoVo, is a well?characterized Dukes?? type C colorectal adenocarcinoma model established from a lymph node metastasis. It exhibits microsatellite instability?high (MSI?H) status and carries an inactivating mutation in the APC tumor suppressor gene, recapitulating key genetic hallmarks of sporadic colorectal cancer. These features render LoVo particularly valuable for studying metastatic progression, epithelial?mesenchymal transition (EMT), and the interplay between Wnt/???catenin and Notch signaling cascades. The adherent epithelial morphology and robust growth characteristics of the parental line are retained in the polyclonal knockout population, ensuring compatibility with standard cell?based assays.
JAG2 encodes the Jagged?2 ligand, a transmembrane protein that trans?activates Notch receptors (NOTCH1, NOTCH2, NOTCH3) on adjacent cells. Ligand?Creceptor engagement triggers sequential proteolytic cleavage by ADAM10 metalloprotease and the ???secretase complex (containing PSEN1), releasing the Notch intracellular domain (NICD). NICD translocates to the nucleus, where it forms a ternary complex with the transcription factor CSL/RBPJ and co?activator MAML1, driving expression of canonical targets such as HES1, HEY1, MYC, and CCND1. This core Notch pathway intersects with Wnt/???catenin, PI3K?AKT, JAK?STAT, and NF???B signaling networks, placing JAG2 at a central hub controlling cell fate determination, proliferation, and differentiation. Upstream regulators include Notch?mediated feedback loops and inflammatory NF???B inputs, while downstream effectors orchestrate broader transcriptional programs.
In the LoVo metastatic colorectal cancer model, JAG2?dependent Notch signaling promotes tumor?promoting processes, including sustained proliferation, migration, invasion, and chemoresistance. Knockout of JAG2 disrupts these oncogenic circuits, making the polyclonal cells an ideal platform for dissecting the specific contributions of Jagged?2 to colorectal cancer pathogenesis. The MSI?H and APC?mutant background of LoVo cells enables focused studies on the crosstalk between aberrant Wnt/???catenin and Notch pathways, which are frequently co?activated in advanced colorectal tumors. Moreover, the polyclonal knockout population can be employed to interrogate ligand?specific versus receptor?specific Notch outputs in a genetic setting that mimics the clonal heterogeneity of patient tumors.
Researchers can apply this model to a wide array of experimental workflows. Notch activation can be quantified by RT?qPCR for HES1 and HEY1, Western blotting for cleaved NICD, or flow cytometry for surface Notch receptor expression following co?culture stimulation. Functional assays include Transwell migration/invasion, MTT proliferation, and spheroid formation to assess metastatic and tumorigenic attributes. Drug sensitivity profiling with ???secretase inhibitors such as DAPT, combined with RNA?seq transcriptomic analyses, reveals JAG2?dependent vulnerabilities and resistance mechanisms. These applications support studies in Notch signaling dissection, colorectal cancer metastasis, epithelial?mesenchymal transition, tumor microenvironment modeling, and anti?Notch therapy development. For further information, please contact Ascent Research.
